ZSAN News and Press, Zosano Pharma Corporation From 05/27/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nvidia (NASDAQ: NVDA ) stock isn’t performing the best today, but investors are still hopeful that it will make a massive surge soon. Source: JHVEPhoto / Shutterstock.com Let’s take a look at wha...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Beyond Meat (NASDAQ: BYND ) stock is getting a boost on Thursday following comments that the plant-based protien company could be the next favorite of Reddit traders. Source: Sundry Photography / Shutterstock.com ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Energy (NASDAQ: VTNR ) stock is on the rise Thursday after the company announced a major acquisition of a refinery belonging to a Royal Dutch Shell (NYSE: RDS.A , RDS.B ) subsidiary. Source: Shutt...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of  Zosano Pharma  (NASDAQ: ZSAN ) surged on Thursday morning following the publication late yesterday of clinical data on long-term use of its Qtrypta migraine treatment. ZSAN stock, which has spent mo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It’s a fantastic day here at InvestorPlace and we plan to keep that mood going! We’re starting off with a look at the biggest pre-market stock movers for Thursday. Source: oneinchpunch/Shut...

Zosano Pharma's (ZSAN) Qtrypta, an intracutaneous (patch) version of Zomig (zolmitriptan), is safe and efficacious when given over the course of a year.New data, published in The Journal of Headache and Pain, found that of 5,963 migraine attacks treated over 12 months, felt pain relief at two...

FREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatme...

FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience fro...

Zosano Pharma (ZSAN): Q1 GAAP EPS of -$0.08 in-line.Revenue of $258kCash and cash equivalents were $26.9M.Shares +1.3%.Press Release For further details see: Zosano Pharma EPS in-line

FREMONT, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021, as well as business highlights. “We have gained clarity from...